Our approach
A new chapter in KRAS-driven cancer treatment.
RAS is one of the most commonly mutated oncogenes in solid tumors, occuring in approximately 20–25% of patients with lung, colorectal, and pancreatic cancers.
The approval of KRAS inhibitors has been an important milestone, offering meaningful benefits to patients and establishing a new standard of care. Yet, their activity can be constrained by tumor heterogeneity and the emergence of resistance, creating an opportunity to further enhance patient outcomes.
Extending the power of targeted therapies toward immunological tumor control.
At Haptena, we are developing a novel approach designed to complement and strengthen the standard of care by acting on highly specific tumor vulnerabilities that emerge in pre-treated KRAS-mutant cancers – with the ambition to expand treatment options for patients who currently face poor prognosis and few alternatives.
Our strategy is built on a deep mechanistic understanding of tumor genetics and immune dynamics, with the goal of developing targeted immunotherapies that can overcome resistance and deliver more durable responses.
How this approach shapes our discovery programs
By integrating precision oncology with immune engineering, Haptena’s research translates mechanistic insights into targeted immunotherapy programs built for oncogene-driven tumors.
This begins with KRAS-mutant cancers, where our understanding of how oncogenic signaling reshapes immune interactions allows us to identify vulnerabilities that traditional therapies do not address.
This scientific approach directly informs how we prioritize targets, how we validate them, and how we advance candidates through early development.